Adage Capital Management

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune and neurodegenerative diseases affecting the body, brain, and eyes. The company leverages its platform technology centered on C1q, a key molecule in the classical complement pathway, to target specific disease processes linked to aberrant activation in these areas. Its primary product candidates include ANX005, which is designed to treat autoimmune and neurodegenerative disorders, and has completed Phase 1b trials for Guillain-Barré syndrome, and ANX007, which targets neurodegenerative ophthalmic disorders and has also finished Phase 1b trials for glaucoma. Additionally, Annexon is exploring treatments for conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company aims to advance its pipeline while considering both orphan and broader market indications.

Menlo Micro, Inc. specializes in the design and development of electronic switches, particularly focusing on electromechanical switch technology. The company's innovative digital-micro-switches are utilized across various industries, including battery management, home automation, electronic vehicles, and medical instrumentation. Their products are engineered to operate effectively under high temperatures and stressful conditions, supporting applications such as high-power tunable resonators, broadband power amplifier impedance matching, and electronically steerable antennas. Menlo Micro also plays a role in advancing the industrial Internet of Things and next-generation 5G mobile networks. Founded in 2016 and based in Irvine, California, the company aims to deliver efficient outcomes through its cutting-edge technology.

Energy Vault SA, founded in 2017 and based in Lugano, Switzerland, specializes in energy storage technology that supports renewable power generation. The company has developed a modular system that employs kinetic energy principles similar to pumped hydro storage, but instead of water, it uses custom-made cylindrical blocks crafted from low-cost materials. This innovative storage solution offers capacities ranging from 10 to 35 MWh and a power output of up to 5 MW, designed to maintain its storage capacity without degradation for over 30 years. Energy Vault's technology aims to provide reliable baseload power, making it an environmentally friendly option for energy storage and transmission.

ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Pyramid Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts, established in 2015. The company specializes in discovering and developing targeted therapeutics that address disorders regulated by the tropomyosin receptor kinase (TRK) family. Its pipeline includes TRK modulators aimed at treating dermatology and oncology disorders linked to the dysregulation of the TRK signaling pathway. Notable products in development include PBI-100, which offers anti-itch, anti-inflammatory, and antiproliferative effects for dermatological conditions, and PBI-200, an orally active TRK inhibitor designed to overcome resistance mutations associated with existing TRK inhibitor therapies in oncology. By selectively modulating TRK receptors, Pyramid Biosciences aims to control key signaling pathways, thus enabling healthcare professionals to manage symptoms and influence disease progression effectively.

Beckley Psytech Limited manufactures psychedelic drug for treating psychiatric and neurological diseases. Beckley Psytech Limited was formerly known as Beckley Psychedelics Limited and changed its name to Beckley Psytech Limited in May 2020. The company was founded in 2014 and is based in Oxford, United Kingdom.

goPuff is a Philadelphia-based startup that delivers products like over-the-counter medicine, baby food, and alcohol. goPuff was founded in 2013 by Yakir Gola and Rafael Ilishayev, two Drexel University students with a minivan and a vision to make everyday life a little easier. What started as a snack delivery service quickly grew into a national essential, and food delivery service, and later, in some markets, alcohol delivery. Today, goPuff is the fastest growing delivery service, operating 24/7 in most major markets. goPuff makes sure its customers have everything they need: from quick meals, over-the-counter meds, snacks and drinks to electronics, office supplies, baby and pet essentials, and in some markets, beer, wine, and spirits. Across America, goPuff is known for satiating late-night cravings for Ben and Jerry’s ice cream, Doritos, Red Bull, and, in select markets, White Claw and rescuing those in need of diapers, condoms, and cleaning products. goPuff allows users the joy of browsing the shelves without the hassle of going to the store. It takes seconds to navigate the app and minutes for goPuff’s Driver-Partners to deliver the customer’s needs and wants. goPuff’s strategically located facilities cut out the middleman allowing for a flat fee of $1.95. goPuff’s success has allowed the company to support important causes. In March 2020 goPuff committed to $1 million in orders to hospital workers fighting COVID-19. In May 2020 the company wrote a check for $1 million to match donations to Boys and Girls Clubs. In June 2020 goPuff committed to supporting underrepresented founders in Philadelphia.

Goat is a global marketplace specializing in authentic sneakers, apparel, and accessories from contemporary luxury brands. Established in 2015 by Daishin Sugano and Eddy Lu in Culver City, California, Goat operates under the GOAT and Flight Club brands, providing a platform that bridges the gap between primary and resale markets. The company offers an extensive selection of styles, allowing users to shop for exclusive drops, make offers on desired items, and explore iconic pieces from various eras. With a community of over 20 million members across 164 countries, Goat has transformed sneaker commerce through innovative technology and services. The company manages 13 physical retail locations and distribution centers in the United States, Asia, and Europe, shipping products to 170 international markets. Goat features over 350 brands, supported by strategic investors such as Foot Locker, Inc. and prominent venture capital firms.

ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging to enhance patient selection and monitor treatment progress for cancer immunotherapy. Founded in 2007 and headquartered in Inglewood, California, the company develops highly targeted diagnostic imaging agents based on engineered antibody fragments, known as minibodies. These minibodies are designed to image specific molecular targets using standard Positron Emission Tomography (PET) technology. ImaginAb's portfolio includes precision imaging products such as CD8 (IAB22M2C) and CD4 for immune-oncology applications, as well as PSMA PET (IAB2M) for prostate cancer. The company’s innovative platform technology allows for the rapid engineering of these antibody fragments, optimizing them for clinical imaging while maintaining their specificity and effectiveness in addressing the diagnostic needs in oncology.

Forter, Inc. specializes in providing comprehensive e-commerce fraud prevention solutions for online merchants. Founded in 2013 and headquartered in New York, with additional offices in London and a research facility in Tel Aviv, the company offers a Decision-As-a-Service platform that utilizes a variety of data points, including cyber intelligence and behavioral analysis, to assess transactions. This system allows merchants to make informed fraud decisions with a transparent view provided through the Forter Decision Dashboard. Additionally, Forter Smart Routing enhances the payment process by preventing revenue loss from false declines. The platform is fully automated, focusing on creating a fraud-free environment that not only blocks fraudulent activities but also improves customer experience and transaction approvals. Forter aims to streamline risk management for e-commerce businesses, ensuring a secure and efficient transaction process.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

SiMa.ai is a machine learning company based in San Jose, California, that specializes in developing high-performance computing solutions for embedded systems. Incorporated in 2018, the company focuses on delivering a machine learning platform that offers single-chip solutions tailored for various applications, particularly in computer vision at the embedded edge. SiMa.ai's technology provides machine learning capabilities with performance ranging from 50 TOPs at 5W to 200 TOPs at 20W, emphasizing low power consumption while maximizing efficiency. Additionally, their solutions include robust security features that can detect potential threats, such as hackers. The team at SiMa.ai comprises technology experts dedicated to providing customers with optimal performance measured in frames per second per watt.

Stem brings and optimizes energy consumption to business through its distributed storage technology. Since 2009, Stem has been analyzing how various types of businesses use electricity and how they are charged for it. The company uses this information to design a solution that protects companies from unnecessarily high electricity costs without requiring any changes to the way they run their businesses. Stem combines big data, predictive analytics and energy storage to reduce electric costs for businesses and in aggregate, deliver services to the grid.

Arch Oncology is an immuno-oncology company focused on developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Founded in 2006 and based in St. Louis, Missouri, with a corporate office in Brisbane, California, the company aims to create innovative therapies that leverage both adaptive and innate immune responses. Arch Oncology's approach involves a new class of checkpoint inhibitors, which represents a significant advancement in cancer treatment. Through its research and development efforts, the company seeks to improve outcomes for patients battling various forms of cancer.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

HawkEye 360, Inc. is a data analytics company specializing in radio frequency (RF) mapping through its commercial satellite constellation. Founded in 2015 and headquartered in Herndon, Virginia, the company focuses on identifying, processing, and geolocating a wide range of RF signals. Its services include maritime domain awareness and spectrum mapping, which are utilized by various commercial, government, and international clients. The insights generated by HawkEye 360's platform support applications in maritime monitoring, intelligence gathering, telecommunications, and crisis response, enabling users to address complex challenges effectively. The company has established a strategic partnership with Ursa to enhance its offerings.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.

Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.

HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders. It creates human-relevant systems to accurately replicate the biology of organ systems and diseases for use throughout drug discovery and development. They work strategically in partnerships with pharmaceutical, biotechnology, and medical device companies. It generates meaningful human response data to increase confidence in decision-making, reduce the risk of costly failures, and identify efficacious therapies.

MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Flame Biosciences, Inc operates as a clinical stage company that engages in the research, development, and commercialization of transformative therapies for cancer and other inflammatory conditions. It offers FL-101 therapy for the treatment of lung cancers that are driven by inflammation; and FL-201 for reducing the chronic inflammation in patients. The company was incorporated in 2017 and is based in New York, New York.

Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Pyramid Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts, established in 2015. The company specializes in discovering and developing targeted therapeutics that address disorders regulated by the tropomyosin receptor kinase (TRK) family. Its pipeline includes TRK modulators aimed at treating dermatology and oncology disorders linked to the dysregulation of the TRK signaling pathway. Notable products in development include PBI-100, which offers anti-itch, anti-inflammatory, and antiproliferative effects for dermatological conditions, and PBI-200, an orally active TRK inhibitor designed to overcome resistance mutations associated with existing TRK inhibitor therapies in oncology. By selectively modulating TRK receptors, Pyramid Biosciences aims to control key signaling pathways, thus enabling healthcare professionals to manage symptoms and influence disease progression effectively.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.

Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune and neurodegenerative diseases affecting the body, brain, and eyes. The company leverages its platform technology centered on C1q, a key molecule in the classical complement pathway, to target specific disease processes linked to aberrant activation in these areas. Its primary product candidates include ANX005, which is designed to treat autoimmune and neurodegenerative disorders, and has completed Phase 1b trials for Guillain-Barré syndrome, and ANX007, which targets neurodegenerative ophthalmic disorders and has also finished Phase 1b trials for glaucoma. Additionally, Annexon is exploring treatments for conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company aims to advance its pipeline while considering both orphan and broader market indications.

Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.

Tanium Inc. is a provider of security and management solutions designed for enterprises and government organizations to effectively manage and secure their computer assets. The company offers a comprehensive platform that enables real-time data collection and management of millions of endpoints, ensuring visibility and accuracy in monitoring endpoint security. Key offerings include the Tanium Endpoint Platform for endpoint control, Tanium Asset for inventory tracking, and Tanium Deploy for software installation and updates. Additional tools such as Tanium Patch and Tanium Performance assist in patch management and end-user experience management, respectively. Tanium also emphasizes cost reduction in management and infrastructure while enhancing operational efficiency. The company serves various industries, including banking and retail, and has established strategic partnerships with firms like PwC and Palo Alto Networks. Founded in 2007, Tanium is headquartered in Kirkland, Washington, and has expanded its presence with offices in multiple locations worldwide.

MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Engage Therapeutics is a biopharmaceutical company based in Summit, New Jersey, focused on developing innovative rescue therapies for individuals experiencing uncontrolled epileptic seizures. The company's lead investigational product, Staccato® alprazolam, is a handheld drug-device combination that utilizes an FDA-approved delivery system along with the approved medication alprazolam. This product aims to provide a rapid response to active and acute seizures. Preliminary results from a Phase 2a proof of concept study indicated that Staccato alprazolam effectively reduced seizures in a photosensitivity model. Engage Therapeutics plans to advance this product through clinical development using the 505(b)(2) regulatory pathway. The company operates as a subsidiary of UCB SA.

ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging to enhance patient selection and monitor treatment progress for cancer immunotherapy. Founded in 2007 and headquartered in Inglewood, California, the company develops highly targeted diagnostic imaging agents based on engineered antibody fragments, known as minibodies. These minibodies are designed to image specific molecular targets using standard Positron Emission Tomography (PET) technology. ImaginAb's portfolio includes precision imaging products such as CD8 (IAB22M2C) and CD4 for immune-oncology applications, as well as PSMA PET (IAB2M) for prostate cancer. The company’s innovative platform technology allows for the rapid engineering of these antibody fragments, optimizing them for clinical imaging while maintaining their specificity and effectiveness in addressing the diagnostic needs in oncology.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

WellDoc, Inc. specializes in developing technology solutions aimed at managing chronic diseases, particularly diabetes. The company offers DiabetesManager, a patient-centric platform designed to facilitate the coordination of diabetes care between patients and healthcare providers. This platform includes features such as personalized coaching, medication reminders, alerts for out-of-range metrics, and family connectivity, all supported by cloud-based analytics and clinical decision-making tools. Additionally, WellDoc provides BlueStar, a mobile prescription therapy solution that offers real-time guidance for diabetes self-management. The company supports a variety of stakeholders, including private and public payors, pharmaceutical firms, and healthcare systems, with services that encompass clinical requirements, software development, and behavioral health programs. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc aims to enhance patient outcomes and reduce healthcare costs by integrating clinical and behavioral applications with everyday technologies.

Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.

Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.

Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. The company utilizes a unique platform based on live, attenuated bacteria engineered to deliver antigen/adjuvant fusion proteins, which aim to enhance the immune response against cancer. Advaxis is actively developing therapies for HPV-related cancers, including axalimogene filolisbac, currently in a Phase II clinical trial for head and neck cancer. Other products in development include ADXS-PSA for prostate cancer, ADXS-NEO for individualized treatment using neoantigens from a patient’s tumor, ADXS-HOT for generating robust anti-cancer immunity, and ADXS-HER2 targeting HER2-positive tumors. Advaxis has established collaborations and licensing agreements with various organizations to further advance its research and development efforts. The company was founded in 2002 and continues to progress its innovative treatments through multiple clinical trials.

MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.

Adverum Biotechnologies is a clinical-stage gene therapy company based in Redwood City, California, focused on developing innovative therapies for ocular and rare diseases. Its primary product candidate, ADVM-022, is designed for the treatment of wet age-related macular degeneration through a single intravitreal injection that aims to provide long-lasting therapeutic effects. The company's pipeline also includes ADVM-043, targeting alpha-1 antitrypsin deficiency, and ADVM-053, which is in preclinical development for hereditary angioedema. Adverum collaborates with Editas Medicine to utilize its proprietary AAV vectors for genome editing in inherited retinal diseases and has a partnership with Regeneron Pharmaceuticals to explore multiple ocular therapeutic targets. Originally known as Avalanche Biotechnologies, the company rebranded in May 2016 following a merger with Annapurna Therapeutics, further advancing its mission to deliver effective treatments for chronic and debilitating conditions.

Nexvet Australia Pty Ltd, a biopharmaceutical company, develops biological therapies for companion animals. It develops drugs in the areas of chronic pain, immune oncology, chronic inflammation, and allergy. Nexvet Australia Pty Ltd was formerly known as Nexvet Biopharma Pty Ltd. The company was founded in 2010 and is based in Melbourne, Australia with a biopharmaceutical manufacturing facility in Tullamore, Ireland. Nexvet Australia Pty Ltd operates as a subsidiary of Zoetis Inc.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.

Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.